FerroKin Biosciences
acquired by ShireSan Carlos, US · Founded 2007 · 1 known investors
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
Biotech
Founders & leadership
MS
Marten SteenNamed on SEC filing
HY
Hugh Y. Rienhoff, Jr., M.D.Named on SEC filing
DH
Dennis Henner, Ph.D.Named on SEC filing
BE
Bryant E. FongNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2012
▶$3MraisedFeb 2012 · 6 investors · BiotechnologyRule 506(b)
▶$3MraisedFeb 2012 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marten SteenDirector
- Hugh Y. Rienhoff, Jr., M.D.Executive Officer, Director
- Dennis Henner, Ph.D.Director
- Bryant E. FongDirector
- Offering amount
- $6M
- Amount sold
- $3M
- Minimum investment
- $1
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware, 2007
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does FerroKin Biosciences do?
- Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
- Who are FerroKin Biosciences's investors?
- FerroKin Biosciences's investors include MC Healthcare Ventures.
- How much funding has FerroKin Biosciences raised?
- FerroKin Biosciences has disclosed $3M raised across 1 round.
- Who acquired FerroKin Biosciences?
- FerroKin Biosciences was acquired by Shire.
- Where is FerroKin Biosciences headquartered?
- FerroKin Biosciences is headquartered in San Carlos, US.